BUZZ-MIRA Pharmaceuticals jumps as oral pain drug beats morphine in animal study
MIRA Pharmaceuticals' shares surged 90% to $2.52 in premarket trading after its oral drug, Mira-55, outperformed morphine in an animal study for chronic inflammatory pain. The drug effectively normalized pain levels and reduced inflammation by targeting CB2 receptors, while morphine only partially alleviated inflammation. This positive data supports MIRA's plans for a marketing application for Mira-55. Year-to-date, shares have increased approximately 16%.
Shares of drug developer MIRA Pharmaceuticals (MIRA.O) rise 90% to $2.52 premarket
Company says its experimental oral drug, Mira-55, eased pain and reduced swelling better than injected morphine in a pre-clinical animal study for chronic inflammatory pain
Mira-55 brought pain levels back to normal and directly reduced inflammation by targeting the CB2 receptor - MIRA
CB2 receptors are expressed in immune cells and are involved in the regulation of immune responses and inflammation
Company says morphine only partially reduced inflammation
Data supports marketing application plans for Mira-55 for chronic inflammatory pain - MIRA
Up to last close, shares up ~16% YTD
